111 related articles for article (PubMed ID: 23165154)
1. Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in Cynomolgus monkeys.
Tian J; Du G; Ye L; Yu X; Zhang J; Wang H; Yu P; Fu F; Liu W; Li Y; Cen X; Guan X
Food Chem Toxicol; 2013 Feb; 52():143-52. PubMed ID: 23165154
[TBL] [Abstract][Full Text] [Related]
2. Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in SD rats.
Ye L; Guan X; Tian J; Zhang J; Du G; Yu X; Yu P; Cen X; Liu W; Li Y
Food Chem Toxicol; 2013 Jun; 56():81-92. PubMed ID: 23454207
[TBL] [Abstract][Full Text] [Related]
3. Lipopolysaccharide/D-galactosamine-induced acute liver injury could be attenuated by dopamine receptor agonist rotigotine via regulating NF-κB signaling pathway.
Yue S; Wang T; Yang Y; Fan Y; Zhou L; Li M; Fu F
Int Immunopharmacol; 2021 Jul; 96():107798. PubMed ID: 34162160
[TBL] [Abstract][Full Text] [Related]
4. A 12-week intramuscular toxicity study of risperidone-loaded microspheres in Beagle dogs.
Tian J; Wang W; Ye L; Cen X; Guan X; Zhang J; Yu P; Du G; Liu W; Li Y
Hum Exp Toxicol; 2014 May; 33(5):473-87. PubMed ID: 23925946
[TBL] [Abstract][Full Text] [Related]
5. Effects of rotigotine and rotigotine extended-release microsphere therapy on myocardial ischemic injury in mice.
Lv H; Yu F; Sha C; Huang Y; Lu Y; Zhang L; Zhai R; Wang T; Fu F
Eur J Pharm Sci; 2019 Jun; 134():1-6. PubMed ID: 30959104
[TBL] [Abstract][Full Text] [Related]
6. A 12-week subchronic intramuscular toxicity study of risperidone-loaded microspheres in rats.
Zhang J; Ye L; Wang W; Du G; Yu X; Zhu X; Dong Q; Cen X; Guan X; Fu F; Tian J
Hum Exp Toxicol; 2015 Feb; 34(2):205-23. PubMed ID: 24812153
[TBL] [Abstract][Full Text] [Related]
7. 20-Week intramuscular toxicity study of rotigotine behenate extended-release microspheres for injection via intramuscular injection in cynomolgus monkeys.
Zhao X; Guo C; Zhang H; Yu X; Zhu X; Du G; Tian J; Liu W; Song T; Chen X; Guo W
Food Chem Toxicol; 2024 Jun; 190():114786. PubMed ID: 38849048
[TBL] [Abstract][Full Text] [Related]
8. Preparation of rotigotine-loaded microspheres and their combination use with L-DOPA to modify dyskinesias in 6-OHDA-lesioned rats.
Wang A; Wang L; Sun K; Liu W; Sha C; Li Y
Pharm Res; 2012 Sep; 29(9):2367-76. PubMed ID: 22549738
[TBL] [Abstract][Full Text] [Related]
9. The development of the rotigotine transdermal patch: a historical perspective.
Waters C
Neurol Clin; 2013 Aug; 31(3 Suppl):S37-50. PubMed ID: 23931953
[TBL] [Abstract][Full Text] [Related]
10. Rotigotine-loaded microspheres exerts the antinociceptive effect via central dopaminergic system.
Li T; Wang L; Zhang L; Li B; Wang D; Zhang L; Wang T; Fu F
Eur J Pharmacol; 2021 Nov; 910():174443. PubMed ID: 34464604
[TBL] [Abstract][Full Text] [Related]
11. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease.
LeWitt PA; Boroojerdi B; MacMahon D; Patton J; Jankovic J
Clin Neuropharmacol; 2007; 30(5):256-65. PubMed ID: 17909303
[TBL] [Abstract][Full Text] [Related]
12. Protection of MPTP-induced neuroinflammation and neurodegeneration by rotigotine-loaded microspheres.
Yu X; Yao JY; He J; Tian JW
Life Sci; 2015 Mar; 124():136-43. PubMed ID: 25640758
[TBL] [Abstract][Full Text] [Related]
13. Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome.
Benitez A; Edens H; Fishman J; Moran K; Asgharnejad M
Ann N Y Acad Sci; 2014 Nov; 1329():45-66. PubMed ID: 25145951
[TBL] [Abstract][Full Text] [Related]
14. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
Splinter MY
Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
[TBL] [Abstract][Full Text] [Related]
15. Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease.
Naidu Y; Chaudhuri KR
Expert Opin Drug Deliv; 2007 Mar; 4(2):111-8. PubMed ID: 17335409
[TBL] [Abstract][Full Text] [Related]
16. Effects of rotigotine transdermal system on non-motor symptoms in Parkinson's disease: an overview.
Zesiewicz TA; Martinez-Martin P
Expert Rev Neurother; 2013 Dec; 13(12):1329-42. PubMed ID: 24236902
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of rotigotine clinical trials: effects on motor and nonmotor symptoms of Parkinson's disease.
Lyons KE; Pahwa R
Neurol Clin; 2013 Aug; 31(3 Suppl):S51-9. PubMed ID: 23931954
[TBL] [Abstract][Full Text] [Related]
18. Treatment of motor and NMS of Parkinson's disease with the rotigotine transdermal system.
Lyons KE
Neurol Clin; 2013 Aug; 31(3 Suppl):vii-ix. PubMed ID: 23931955
[No Abstract] [Full Text] [Related]
19. Rotigotine transdermal patch in combination therapy for Parkinson's disease--observations in routine clinical practice.
Ceballos-Baumann A; Häck HJ
Curr Med Res Opin; 2011 Oct; 27(10):1899-905. PubMed ID: 21867400
[TBL] [Abstract][Full Text] [Related]
20. Dopamine receptor agonist rotigotine-loaded microspheres ameliorates sexual function deteriorated by fluoxetine in depression rats.
Wang W; Zhang C; Fan Y; Yue S; Yang Y; Liu R; Zhang L; Wang T; Fu F
ASN Neuro; 2021; 13():17590914211052862. PubMed ID: 34724850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
